Sofosbuvir + Ribavirin in HCV-HIV Coinfection: HCV GT 1,2,3,4
PHOTON-2 Trial

PHOTON-2 Trial: Study Features

**Design**: Open-label, nonrandomized, uncontrolled, phase 3 trial using sofosbuvir + ribavirin for HCV GT 1, 2, 3, or 4 in persons coinfected with HIV

**Setting**: 45 clinics in Europe

**Entry Criteria**
- HIV coinfection; HCV Genotype 1, 2, 3, or 4
- Age 18 or older
- HCV treatment naïve (GT 1-4) or treatment experienced (GT 2 or 3)
- On HIV ARV Rx with HIV RNA ≤ 50 copies/ml and CD4 >200 cells/mm³
- Not on HIV ARV Rx and CD4 > 500 cells/mm³
- ARV regimen allowed: tenofovir-emtricitabine plus either ritonavir boosted atazanavir or darunavir, efavirenz, rilpivirine, or raltegravir
- Compensated cirrhosis permitted (up to 20% of subjects); no platelet cutoff

**Primary End-Points**
- Efficacy (SVR12), safety, and impact on HIV
Sofosbuvir plus Ribavirin for HCV-HIV Coinfection
PHOTON-2 Trial: Treatment Arms

**Drug Dosing**
- **Sofosbuvir:** 400 mg once daily
- **Ribavirin (weight-based and divided bid):** 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg

**Source:** Molina JM, et al. Lancet. 2015;385:1098-106.
Sofosbuvir plus Ribavirin for HCV-HIV Coinfection
PHOTON-2 Trial: Results

PHOTON-2: SVR12 with Sofosbuvir + RBV x 12-24 weeks

- GT 1: 95/112 (85%)
- GT 2: 17/19 (89%)
- GT 3: 52/57 (91%)
- GT 4: 26/31 (84%)
- GT 2 Treatment Naive: 5/6 (83%)
- GT 3 Treatment Experienced: 42/49 (86%)

All received 24-week Rx except 12 week Rx with GT-2 Treatment Naive

Sofosbuvir plus Ribavirin for HCV-HIV Coinfection

PHOTON-2 Trial: Results

PHOTON-2: SVR12 with Sofosbuvir + RBV, by Genotype

Sofosbuvir and Ribavirin for HCV-HIV Coinfection
PHOTON-2 Trial: Interpretation

**Interpretation:** “Sofosbuvir and ribavirin provided high rates of sustained virological response after 12 weeks of treatment in treatment-naive and treatment-experienced patients co-infected with HIV and HCV genotypes 1–4. The characteristics of this interferon-free combination regimen make sofosbuvir plus ribavirin a useful treatment option for this patient population.”

This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects.

Hepatitis C Online
www.hepatitisc.uw.edu

Hepatitis Web Study
http://depts.washington.edu/hepstudy/

Funded by a grant from the Centers for Disease Control and Prevention.